Pregabalin Capsule
Product Images NDC 69367-426

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 69367-426). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin, showing the arrangement of its atoms including a carboxylic acid group (CO2H) and an amine group (NH2) attached to a carbon chain with side groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin capsules at doses of 200 mg, 100 mg, and 25 mg taken three times a day, as well as a placebo. The graph shows different response rates across these groups over a range of pain improvement percentages.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg taken three times a day and placebo. The y-axis shows the percent of patients improved, and the x-axis shows the percent improvement in pain, with two vertical reference lines at 30% and 50% improvement. Pregabalin shows consistently higher patient improvement percentages than placebo across the pain improvement range.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin oral capsules at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared to placebo. The graph depicts higher patient improvement percentages for the higher Pregabalin doses compared to placebo.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line) in terms of pain improvement percentage.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing the percentage of patients improved by percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows percent of patients improved (0 to 100%). The graph includes three lines: dashed for Pregabalin 100 mg, solid for Pregabalin 50 mg, and dotted for placebo, illustrating comparative treatment effects.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar graph showing responder rates (%) for pregabalin at various daily doses versus placebo in two studies, E1 and E3. The x-axis indicates doses and regimens (BID or TID), and the y-axis shows responder rates ranging from 0% to 60%. Study E1 presents data for placebo and five pregabalin doses (50, 150, 300, 600 mg/day BID). Study E3 compares placebo with 600 mg/day administered BID and TID.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph illustrating seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin across four studies (E1 BID, E2 TID, E3 BID, E3 TID). The x-axis represents dose from 0 to 600 mg/day, and the y-axis shows seizure reduction from -10% to 60%. Significant p-values are indicated at various doses, with placebo corresponding to dose 0.*

FDA Label Image

Figure 8 (Pregabalin 09)

A bar graph showing responder rates in a percentage comparing three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day treatment (29.1%, N=103), and 10 mg/kg/day treatment (40.6%, N=96). The vertical axis represents responder rate (%) from 0 to 60, while the horizontal axis lists the treatment groups with sample sizes.*

FDA Label Image

Figure 9 (Pregabalin 10)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 600 mg daily doses compared to placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percent of patients improved (0 to 100%). Four lines display different dosages and placebo outcomes over the pain improvement scale.*

FDA Label Image

Figure 10 (Pregabalin 11)

A Kaplan-Meier survival curve graph showing the estimated percentage of subjects without LTR (loss of therapeutic response) over time in days. The solid line represents Pregabalin, and the dashed line represents Placebo, illustrating differing survival probabilities without LTR between treatment groups.*

FDA Label Image

Figure 11 (Pregabalin 12)

A line graph depicting the percent of subjects improved over time from baseline to week 12 in a BOCF analysis. Two lines compare Pregabalin (solid) and Placebo (dashed), showing higher improvement percentages for Pregabalin across various thresholds of improvement.*

FDA Label Image

Figure 12 (Pregabalin 13)

A line graph depicting the percent of subjects improved from baseline to Week 16, measured by BOCF. The x-axis shows percent improved from baseline ranging from 0 to 100, and the y-axis shows percent of subjects improved from 0 to 100. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, illustrating higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Pregabalin Capsules 25 mg oral dosage form in a bottle containing 90 capsules. The label shows the product is manufactured by Eskayef Pharmaceuticals Limited and labeled for Westminster Pharmaceuticals, LLC. It includes storage instructions and a barcode. The NDC number is 69367-424-09.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Pregabalin Capsules 50 mg, oral dosage form, containing 90 capsules. The label includes the NDC number 69367-425-09 and instructions for pharmacists to dispense the accompanying Medication Guide. It is manufactured for Westminster Pharmaceuticals, LLC, Nashville, TN, and by Eskayef Pharmaceuticals Limited in Bangladesh. Storage instructions and dosing notes are also provided.*

FDA Label Image

Principal Display Panel (75 mg Capsule Bottle Label)

Pregabalin Capsules 75 mg oral dosage form with 90 capsules per bottle, labeled for prescription use only. The label includes handling and storage instructions, manufacturer information showing Eskayef Pharmaceuticals Limited, and the labeler Westminster Pharmaceuticals, LLC. The NDC number is 69367-426-09.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Label for Pregabalin 100 mg capsules by Westminster Pharmaceuticals, LLC. The label indicates Prescription Only status, a package quantity of 90 capsules, and directs pharmacists to dispense the Medication Guide. Storage instructions and manufacturer details (Eskayef Pharmaceuticals Limited, Bangladesh) are also included alongside a barcode.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Label for Pregabalin Capsules 150 mg by Westminster Pharmaceuticals, LLC. The label includes dosage strength, storage instructions, and directs pharmacists to dispense the accompanying Medication Guide. Manufactured by Eskayef Pharmaceuticals Limited in Bangladesh. Package contains 90 capsules with a barcode and contact information for Westminster Pharmaceuticals in Nashville, TN.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Label for Pregabalin Capsules 200 mg by Westminster Pharmaceuticals, LLC. The package contains 90 capsules. The label includes storage instructions, manufacturing details by Eskayef Pharmaceuticals Limited in Bangladesh, and a barcode. It specifies that each capsule contains 200 mg pregabalin and is for prescription use only.*

FDA Label Image

Principal Display Panel (225 mg Capsule Bottle Label)

Pregabalin Capsules 225 mg oral capsules label. The label states the product name, strength, and quantity of 90 capsules. It includes storage instructions, dispensing guidelines, and manufacturer details, listing Westminster Pharmaceuticals, LLC as the labeler and Eskayef Pharmaceuticals Limited in Bangladesh as the manufacturer. A barcode and NDC 69367-430-09 are visible.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

Label for Pregabalin Capsules 300 mg, manufactured by Westminster Pharmaceuticals, LLC. The label indicates 90 capsules per package. It includes storage instructions and manufacturer details for Eskayef Pharmaceuticals Limited in Bangladesh, along with a barcode and contact information for Westminster Pharmaceuticals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.